Positioning Mason's Regional Biocontainment Laboratory for Effective Pandemic Preparedness

梅森的区域生物防护实验室定位为有效的流行病防范

• 批准号: 10793382
• 负责人: Farhang Alem
• 金额: $ 249.52万
• 依托单位: GEORGE MASON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-18 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10793382
• 关键词: Acceleration; Acute; Address; Alphavirus; Animal Experimentation; Applied Research; Basic Science; Biology; Biomedical Research; COVID-19 pandemic; Capital; Certification; Collaborations; Containment; Coronavirus; Data; Diagnostic; Disease Outbreaks; Economic Burden; Emerging Communicable Diseases; Engineering; Ensure; Environment; Face; Filovirus; Funding; Health; Immune response; Individual; Infectious Agent; Infectious Diseases Research; Knowledge; Laboratories; Laboratory Research; Leadership; Learning; Maintenance; Mentorship; Modeling; National Institute of Allergy and Infectious Disease; Organoids; Pathogenesis; Positioning Attribute; Regulation; Research; Research Infrastructure; Research Personnel; Resources; Safety; Secure; Services; System; Testing; Therapeutic; Tissues; Toxic effect; Training; Training Programs; Universities; Update; Vaccines; Virus Diseases; animal imaging; biosafety level 3 facility; drug discovery; efficacy evaluation; future pandemic; good laboratory practice; improved; in vivo; innovation; laboratory facility; lead optimization; microphysiology system; operation; organ on a chip; pandemic preparedness; pathogen; pre-clinical; preclinical study; product development; programs; promote resilience; research and development; response; safety assessment; safety practice; success; training opportunity; transmission process

OVERALL CORE ABSTRACT George Mason University (GMU) Biomedical Laboratory (BRL) is one of 12 Regional Biocontainment Laboratories (RBLs) established through NIAID support in the early 2000s to serve as Biosafety Level 3 (BSL-3) facilities to conduct cutting edge pathogen research and serve as resources to rapidly address emerging infectious disease outbreaks. The BRL serves as a center for scientific collaboration to 1) generate advanced knowledge of pathogen biology and host interaction mechanisms, and 2) evaluate diagnostics, therapeutics and vaccines. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic exposed critical vulnerabilities to the nation’s BSL-3 research infrastructure, including the GMU BRL facility. GMU learned that there are gaps and opportunities to enhance safe BRL operations management to more effectively face sudden disease outbreaks and support a more robust pipeline of innovations for response to future pandemics. This proposal outlines activities for three cores to enhance the BRL facility, increase high containment training, and provide additional BSL-3 research services for pre-clinical innovation. The GMU RBL will 1) Implement a comprehensive BSL-3 facilities preventative maintenance and upgrade plan to ensure continuity of operations, compliance with federal regulations, and a safe and secure facility; 2) Enhance safety and quality of BSL-3 laboratory practices; and 3) Create two new research cores in high containment. The expanded Microphysiological Systems (MPS) core will enable organ-on-a- chip (OOC) and organoid models for lead optimization, safety assessment, off target effects, toxicity, and efficacy analysis. The Advanced Animal Research (AAR) core will support pre- clinical studies starting with in vivo exposures and countermeasure testing and transitioning to advanced animal imaging, spatial tissue, and cellular analysis. Together, the cores will accelerate vaccine and therapeutic drug discovery and improve understanding of the transmission and pathogenesis of infectious agents as well as host response.

总体核心摘要 乔治梅森大学 (GMU) 生物医学实验室 (BRL) 是 12 个区域性实验室之一 2000 年代初在 NIAID 支持下建立的生物防护实验室 (RBL) 作为生物安全 3 级 (BSL-3) 设施进行尖端病原体研究和 作为快速应对新出现的传染病爆发的资源。 作为科学合作中心，1) 产生病原体生物学的先进知识 和宿主相互作用机制，2) 评估诊断、治疗和疫苗。 严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 大流行暴露了危急情况 国家 BSL-3 研究基础设施（包括 GMU BRL 设施）的漏洞。 GMU 了解到加强巴西雷亚尔安全运营存在差距和机遇 更有效地应对突发疾病爆发并支持更强有力的管理 该提案概述了应对未来流行病的创新渠道。 三个核心，以增强 BRL 设施，增加高遏制训练，并提供 用于临床前创新的额外 BSL-3 研究服务 GMU RBL 将 1) 实施 全面的 BSL-3 设施预防性维护和升级计划，以确保连续性 运营、遵守联邦法规以及安全可靠的设施； 2) 加强 BSL-3 实验室实践的安全性和质量；以及 3) 在高水平领域创建两个新的研究核心 扩展的微生理系统（MPS）核心将使器官在-上。 用于先导化合物优化、安全性评估、脱靶效应的芯片（OOC）和类器官模型， 毒性和功效分析。高级动物研究 (AAR) 核心将支持预分析。 临床研究从体内暴露和对策测试开始，然后过渡到 这些核心将先进的动物成像、空间组织和细胞分析结合在一起。 加速疫苗和治疗药物的发现并提高对疫苗和治疗药物的了解 传染源的传播和发病机制以及宿主反应。